GIOVANNI PIEDIMONTE
Medical Practice at Crandon Blvd, Miami, FL

License number
Florida 109033
Issued Date
Feb 7, 2011
Effective Date
Feb 13, 2015
Expiration Date
Jan 31, 2013
Category
Health Care
Type
Medical Doctor
Address
Address 2
151 Crandon Blvd, Miami, FL 33149
1 Medical Center Dr, Morgantown, WV 26506
Phone
(305) 846-9546

Organization information

See more information about GIOVANNI PIEDIMONTE at bizstanding.com

Giovanni Piedimonte MD,FCCP

1 Stadium Dr, Morgantown, WV 26507

Industry:
Pulmonologist, Pediatric Pulmonologist, Pediatrician
Site:
Phone:
(304) 598-4835 (Phone)
Description:
There are 28 doctors at this site. Surgery is not performed at this site.
Giovanni Piedimonte

Professional information

Giovanni Piedimonte Photo 1

Dr. Giovanni Piedimonte, Cleveland OH - MD (Doctor of Medicine)

Specialties:
Pediatric Pulmonology
Address:
9500 Euclid Ave, Cleveland 44195
(216) 444-2344 (Phone), (216) 445-3797 (Fax)
PHYSICIAN OFFICE CENTER
1 1 Stadium Dr Dr, Morgantown 26506
(304) 598-4820 (Phone), (304) 293-6963 (Fax)
1 Stadium Dr STE 3, Morgantown 26506
(304) 598-4000 (Phone), (304) 598-6061 (Fax)
Certifications:
Pediatric Pulmonology, 2004, Pediatrics, 2001
Awards:
Healthgrades Honor Roll
Languages:
English, Italian
Hospitals:
9500 Euclid Ave, Cleveland 44195
1 Stadium Dr STE 3, Morgantown 26506
PHYSICIAN OFFICE CENTER
1 1 Stadium Dr Dr, Morgantown 26506
Princeton Community Hospital
122 12Th Street Ext, Princeton 24740
Wheeling Hospital
1 Medical Park, Wheeling 26003
Education:
Medical School
University of Roma-La Sapienza / Faculty of Medicine And Surgery


Giovanni Piedimonte Photo 2

Nk-1 Receptor Antagonists For Prevention Of Neurogenic Inflammation In Gene Therapy

US Patent:
6562335, May 13, 2003
Filed:
May 18, 1998
Appl. No.:
09/077045
Inventors:
Giovanni Piedimonte - Miami FL
Hans J. Hess - Old Lyme CT
Assignee:
Pfizer, Inc. - New York NY
International Classification:
A61K 4800
US Classification:
424 932, 514 44, 5145275, 4353201
Abstract:
The present invention relates to a method for inhibiting a neurogenic inflammation caused or potentiated by an administration of viral vectors in gene therapy by administering to said mammal an antagonist that binds to a NK-1 receptor in an amount that is effective to inhibit said neurogenic inflammation.